Primary, pulmonary providers endorse lung CA screening

October 12, 2017

(HealthDay)—Primary care clinicians and pulmonologists endorse lung cancer screening (LCS), but there are limitations in their knowledge of screening components, according to a study published online Sept. 21 in the Annals of the American Thoracic Society.

Matthew Triplette, M.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted an electronic survey of primary care and pulmonary providers to examine knowledge, beliefs, attitudes, barriers, and facilitators related to LCS. There were 196 participants; 80 percent of them were primary care clinicians, 19 percent were pulmonologists, and 1 percent were others.

The researchers found that 74 percent of participants endorsed the effectiveness of LCS; performance was suboptimal on knowledge-based assessments of eligibility, documentation, and nodule management. Key barriers included inadequate time and staffing (both 36 percent), and not addressing screening because patients had too many other illnesses (38 percent). Decision aids, used at the point-of-referral, were important clinical facilitators of LCS (51 percent) and facilitators of provider knowledge (59 percent). Several differences were seen by provider specialty, including primary care clinicians more often reporting time constraints and their patients having too many other illnesses to address screening.

"Providers endorsed the benefits of LCS, but there are limitations in provider knowledge of key screening components," the authors write.

Explore further: EHR-based prompt ups hepatitis C screening for baby boomers

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

EHR-based prompt ups hepatitis C screening for baby boomers

July 20, 2017
(HealthDay)—Implementation of an electronic health record (EHR)-based prompt can improve hepatitis C virus (HCV) screening rates among baby boomers, according to a study published online July 17 in Hepatology.

Patient with CAS of 50 percent should not undergo screening

October 3, 2017
(HealthDay)—A vascular surgeon and primary care physician agree that an asymptomatic patient with cardiovascular risk and stenosis of 50 percent on screening carotid ultrasonography should not undergo carotid artery stenosis ...

Many pulmonologists under-, over-screen with LDCT

September 28, 2015
(HealthDay)—Almost half of pulmonologists have a propensity for over- or under-use of low-dose computed tomography (LDCT) screening for lung cancer, according to a study published online Sept. 14 in the Annals of the American ...

CRC screen up for older patients, those not in labor force

July 28, 2017
(HealthDay)—Factors associated with colorectal cancer (CRC) screening rates at U.S. community health centers include age and insurance status, but not patient-provider communication, according to a study published online ...

Age, life expectancy influence termination of PSA screening

April 26, 2012
(HealthDay) -- Most primary care providers consider both a man's age and life expectancy in deciding whether to discontinue prostate-specific antigen (PSA) screenings, but multiple factors are involved in this decision, according ...

Screening patients at high-risk for lung cancer more likely when prmary care provider is familiar with guidelines

October 30, 2014
Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (LDCT) screening when their primary care provider is familiar with guideline recommendations for LDCT screening for ...

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.